Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 29, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy
June 19, 2018 10:28 ET
|
Sarepta Therapeutics, Inc.
-- Biopsies performed at Day 90 showed robust micro-dystrophin expression in muscle measured by all methods and observed in all three patients -- -- Significant decrease in levels of serum creatine...
Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply
June 13, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
-- The partnership will provide commercial supply for a potential micro-dystrophin gene therapy product launch and other neuromuscular programs in the pipeline -- -- Hybrid model enables Sarepta to...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2018 18:10 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Host R&D Day on Tuesday, June 19, 2018
June 08, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Event to be Webcast Live – CAMBRIDGE, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and...
Sarepta Therapeutics Appoints Gilmore O’Neill, M.B., M.M.Sc. as Chief Medical Officer
June 07, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
June 05, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit
June 04, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Dr. Rodino-Klapac, a National Institutes of Health Fellow, is a pioneer in the advancement of gene therapy to treat human disease, whose discoveries have advanced six gene therapy programs from...
As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS® (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe
June 01, 2018 07:00 ET
|
Sarepta Therapeutics, Inc.
-- Sarepta will seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened -- CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...